 Earlier this month, Mallinckrodt succeeded in its inter partes review IPR challenge against patent owner Biovie, Inc. Biovie attempted to use the recent Federal Circuit decision in OSI Pharmaceuticals v. Apotex as a shield to patentability, but the shield was unsuccessful. 